

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.

PHARMA-92

GAU: 1626

EXAMINER: Andrea D. Souza Small

APPLICATION OF: Denis LABRECQUE et al.

SERIAL NO: 10/046,396

FILING DATE: January 16, 2002

FOR: THIOPENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER

REVOCATION AND NEW APPOINTMENT OF POWER OF ATTORNEY

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

SIR:

The undersigned representative of BioChem Pharma Inc. (now doing business as Shire BioChem Inc.), owner by virtue of assignment of the above-identified application, hereby revokes any and all previous Powers of Attorney and appoints I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); James E. Ruland (37,432); Jennifer J. Branigan (40,921) Robert E. McCarthy (46,044); Csaba Henter (50,908) and Nicole E. Kinsey (50,723) as Assignee's attorney with full power of substitution and revocation, to prosecute said patent application, receive any Letters Patent and to take any and all other actions with regard to this patent application and any Letters Patent issuing thereon, and request that all correspondence be sent to the firm of:

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 Clarendon Boulevard,
Suite 1400,
Arlington, Virginia 22201

CERTIFICATION UNDER 37 C.F.R. 3.73(b)

I, the undersigned, certify that I am an individual authorized to act on behalf of BioChem Pharma Inc., the assignee of the entire right, title and interest of the above-identified application by virtue of an assignment from the inventor(s), said Assignment having been recorded in the U.S. Patent and Trademark Office at reel no. 011530, frame(s) 0049.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Apr 10 2003
Date Signed

By: Shona McDiarmid
Title: Vice President,
Global Intellectual Property

Filed: